FT Vest U.S. Equity Deep Buffer ETF – October (BATS:DOCT) Trading Up 0.1% – Still a Buy?
by Mitch Edgeman · The Markets DailyFT Vest U.S. Equity Deep Buffer ETF – October (BATS:DOCT – Get Free Report) traded up 0.1% during trading on Monday . The stock traded as high as $39.11 and last traded at $39.04. 51,179 shares were traded during mid-day trading, The stock had previously closed at $39.01.
FT Vest U.S. Equity Deep Buffer ETF – October Trading Down 0.2 %
The business has a 50 day moving average price of $38.96 and a 200-day moving average price of $38.46. The company has a market cap of $190.34 million, a P/E ratio of 23.49 and a beta of 0.46.
Hedge Funds Weigh In On FT Vest U.S. Equity Deep Buffer ETF – October
An institutional investor recently raised its position in FT Vest U.S. Equity Deep Buffer ETF – October stock. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of FT Vest U.S. Equity Deep Buffer ETF – October (BATS:DOCT – Free Report) by 72.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,922 shares of the company’s stock after purchasing an additional 6,672 shares during the period. Wealth Enhancement Advisory Services LLC owned about 0.34% of FT Vest U.S. Equity Deep Buffer ETF – October worth $599,000 at the end of the most recent reporting period.
FT Vest U.S. Equity Deep Buffer ETF – October Company Profile
The FT Cboe Vest U.S. Equity Deep Buffer ETF – October (DOCT) is an exchange-traded fund that mostly invests in large cap equity. The fund aims for specific buffered losses and capped gains on the SPY over a specific holdings period. The actively-managed fund holds options and collateral. DOCT was launched on Oct 16, 2020 and is managed by First Trust.
Featured Stories
- Five stocks we like better than FT Vest U.S. Equity Deep Buffer ETF – October
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Trading Halts Explained
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Top Biotech Stocks: Exploring Innovation Opportunities
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?